Nikki Swope January 18, 2024 402-471-0042

LB 1094

Revision: 00 FISCAL NOTE LEGISLATIVE FISCAL ANALYST ESTIMATE

ESTIMATE OF FISCAL IMPACT – STATE AGENCIES (See narrative for political subdivision estimates)					
	FY 2024-25		FY 2025-26		
	EXPENDITURES	REVENUE	EXPENDITURES	REVENUE	
GENERAL FUNDS					
CASH FUNDS					
FEDERAL FUNDS					
OTHER FUNDS					
TOTAL FUNDS					

Any Fiscal Notes received from state agencies and political subdivisions are attached following the Legislative Fiscal Analyst Estimate.

LB 1094 proposes to limit the out-of-pocket cost of a two-pack of medically necessary epinephrine injectors to no more than \$60, regardless of the type of epinephrine injector. The effective date is January 1, 2025.

Both the State of Nebraska employees and the University System health plans provide for the coverage as outlined in the bill.

No fiscal impact.

ADMINISTRATIVE SERVICES STATE BUDGET DIVISION: REVIEW OF AGENCY & POLT. SUB. RESPONSE						
LB: 1094	of Nebraska System					
REVIEWED B	Y: Ryan Walton	DATE: 1/22/2024	PHONE: (402) 471-4174			
COMMENTS: The University of Nebraska System's assessment of no fiscal impact from LB 1094 appears reasonable.						
ADMINISTRATIVE SERVICES STATE BUDGET DIVISION: REVIEW OF AGENCY & POLT. SUB. RESPONSE						
LB: 1094 AM: AGENCY/POLT. SUB: Department of Administrative Services (DAS)						
REVIEWED BY: Ryan Walton		DATE: 1/17/2024	PHONE: (402) 471-4174			

COMMENTS: DAS's assessment of fiscal impact from LB 1094 appears reasonable.

Please complete <u>ALL</u> (5) blanks in the first three lines.

LB ⁽¹⁾ 1094			FISCAL NOTE		
State Agency OR Political Subdivision Name: ⁽²⁾	Department of Administrative Services (DAS) -Employee Wellness & Benefits				
Prepared by: ⁽³⁾ Jennifer Norris	Date Prepared: ⁽⁴⁾	Pho	ne: ⁽⁵⁾ 402/480-9728		
ESTIMATE PROVI	DED BY STATE AGEN	CY OR POLITICAL SUB	DIVISION		
<u>FY S</u> EXPENDITURES	2024-25 <u>REVENUE</u>	<u>FY</u> <u>EXPENDITURES</u>	2025-26 <u>REVENUE</u>		
GENERAL FUNDS					
CASH FUNDS					
FEDERAL FUNDS					
REVOLVING FUNDS					
TOTAL FUNDS See Below	See Below	See Below	See Below		

Explanation of Estimate:

LB 1094 proposes to limit the out-of-pocket cost of a two-pack of medically necessary epinephrine injectors to no more than \$60 regardless of the type of epinephrine injector for covered individuals beginning January 1, 2025.

The state's health plan currently already complies with this requirement.

LB 1094 also proposed to require coverage for generic and authorized generic versions of such inhaled prescription corticosteroid medication beginning January 1, 2025.

Regarding inhaled corticosteroid medications, the State's plan currently covers either the generic versions or a lesser cost medication of the same type. There is no way to predict how many prescriptions would switch to a generic version, which could potentially increase plan costs as some brand name drugs on the State's Prescription Drug List (PDL) actually cost the plan less than the generic versions.

Assuming all users were to switch to a more expensive inhaled corticosteroid medication, an estimated maximum increase to the plan costs would be \$146,790 annually. There are approximately 630 users with an average annual increase of \$233 per prescription (630 x \$233 = \$146,790).

The estimated impact for FY24-25 is \$73,395 (the bill is effective January 1, 2025), and \$146,790 in FY25-26.

The State of Nebraska plans are self-insured, any increases may cause an increase to premiums. The state covers 79% of premiums while the employee covers 21%. It is estimated the maximum fiscal impact to the State would be \$57,982 in FY24-25 and \$115,964 in FY25-26

\$73,395 X 79% = \$57,982 \$146,790 X 79% = \$115,964 The table below summarizes the estimated impact by fund type of any premium increases. The allocation by fund type is based on an average for Benefit expenditures over a four-year period (2020-2023).

Fund Type	Expenditures –	Expenditures –
	FY24-25	FY25-26
General Fund	\$29,491	\$58,982
Cash Fund	\$14,542	\$29,084
Federal Fund	\$11,192	\$22,384
Revolving Fund	\$2,757	\$5,514
Total	\$57,982	\$115,964

BREAKDOWN BY MAJOR OBJECTS OF EXPENDITURE Personal Services: NUMBER OF POSITIONS 2024-25 2025-26 POSITION TITLE **EXPENDITURES EXPENDITURES** <u>24-25</u> <u>25-26</u> Benefits..... Operating..... Travel..... Capital outlay..... Aid..... Capital improvements..... TOTAL

LB ⁽¹⁾1094 <u>Provide restrictions on insurance coverage of epinephrine injectors and FISCAL NOTE inhalers</u>

State Agency OR Polition	e Agency OR Political Subdivision Name: ⁽²⁾ University of Nebraska System					
Prepared by: ⁽³⁾ Chris	s Kabourek	Date Prepared: ⁽⁴⁾	01/18/2024	Phone: ⁽⁵⁾	(402) 472-7102	
	ESTIMATE PROVIDED BY STATE AGENCY OR POLITICAL SUBDIVISION					
	F١	⁷ 2024 - 25 FY 2025 - 26				
GENERAL FUNDS	EXPENDITURES	REVENUE 0.00	EXPENDITUR	<u>ES</u>	<u>REVENUE</u> 0.00	
CASH FUNDS	0.00	0.00	0.00		0.00	
FEDERAL FUNDS	0.00	0.00	0.00		0.00	
OTHER FUNDS	0.00	0.00	0.00		0.00	
TOTAL FUNDS	0.00	0.00	0.00		0.00	

Explanation of Estimate:

No fiscal impact

The University's current health plan provides coverage of epinephrine injectors at copay amounts less than the maximum amounts listed in Section 1 of the bill.

The University's current health plan provides coverage of generic and authorized generic versions of inhaled prescription corticosteroid medication as required in Section 2 of the bill.

Personal Services: BREA	AKDOWN BY M	AJOR OBJECTS	OF EXPENDITURE	
POSITION TITLE	NUMBER OF POSITIONS 24 - 25 25 - 26		2024 - 25 <u>EXPENDITURES</u>	2025 - 26 EXPENDITURES
	0	0		
_	0	0		
Benefits				
Operating				
Travel				
Capital outlay				
Aid				
Capital improvements				
TOTAL				

2024